Good evening :)
Place Order
Add to Watchlist

GlaxoSmithKline Pharmaceuticals Ltd

GLAXO

GlaxoSmithKline Pharmaceuticals Ltd

GLAXO
Health CarePharmaceuticals
MidcapWith a market cap of ₹47,153 cr, stock is ranked 192
Moderate RiskStock is 2.62x as volatile as Nifty
2,783.450.81% (+22.30)
2,783.450.81% (+22.30)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
MidcapWith a market cap of ₹47,153 cr, stock is ranked 192
Moderate RiskStock is 2.62x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
MidcapWith a market cap of ₹47,153 cr, stock is ranked 192
Moderate RiskStock is 2.62x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
73.6726.531.15%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
52.296.680.47%

Forecast & Ratings

Detailed Forecast 
50%
Analysts have suggested that investors can buy this stock

from 4 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

GlaxoSmithKline Pharmaceuticals is a pharmaceutical company engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company develops a range of products in pharmaceuticals, vaccines and consumer healthcare.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 1.86%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 1.49% to 0.95%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 5.78%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue2,977.083,029.712,943.803,279.213,850.203,143.704,700.863,365.833,595.993,630.89
Raw Materialssubtract1,377.571,314.381,299.241,332.461,343.301,294.881,340.621,215.921,398.252,674.66
Power & Fuel Costsubtract25.9727.8226.4427.9433.3626.0827.8329.6029.64
Employee Costsubtract443.37483.01523.40537.20628.55616.16610.23594.99624.39
Selling & Administrative Expensessubtract333.63373.99358.84381.41376.88242.05343.67370.30374.73
Operating & Other expensessubtract192.78292.00157.73268.391,073.35357.54215.32248.00281.31
Depreciation/Amortizationsubtract24.9527.0837.9948.5982.6878.6068.1965.7769.6869.73
Interest & Other Itemssubtract0.420.250.190.556.343.532.001.811.801.89
Taxes & Other Itemssubtract202.25174.38189.24237.27212.55166.72398.28228.76226.23244.57
EPS22.2019.8820.7026.295.5021.14100.0436.0534.8337.78
DPS25.0015.0017.5020.0040.0030.0090.0032.0032.0064.00
Payout ratio1.130.750.850.767.271.420.900.890.921.69

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2023

Annual report

PDF

Investor Presentation

Aug 24PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
GlaxoSmithKline Pharmaceuticals Ltd79.9326.531.15%
Sun Pharmaceutical Industries Ltd47.656.800.71%
Cipla Ltd31.274.810.81%
Torrent Pharmaceuticals Ltd71.4517.260.80%

Price Comparison

Compare GLAXO with any stock or ETF
Compare GLAXO with any stock or ETF
GLAXO
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding75.00%4.98%2.36%4.36%13.30%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep2.41%2.50%2.93%3.48%4.02%4.36%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding GlaxoSmithKline Pharmaceuticals Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Aditya Birla Sun Life ELSS Tax Saver Fund - Growth - Direct Plan

Growth
0.5473%1.53%-0.18%17/71 (0)
Kotak Equity Opportunities Fund - Growth - Direct Plan

Growth
0.5355%1.00%-0.04%53/73 (-15)
Nippon India Pharma Fund - Growth - Direct Plan

Growth
0.4858%2.61%-0.37%14/36 (-2)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 1.15%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹11.50 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateMay 31, 2024

Final
Final | Div/Share: ₹32.00

Dividend/Share

32.00

Ex DateEx Date

May 31, 2024

Cash Dividend

Ex DateEx DateJun 30, 2023

Final
Final | Div/Share: ₹32.00

Dividend/Share

32.00

Ex DateEx Date

Jun 30, 2023

Cash Dividend

Ex DateEx DateJul 7, 2022

Special
Special | Div/Share: ₹60.00

Dividend/Share

60.00

Ex DateEx Date

Jul 7, 2022

Cash Dividend

Ex DateEx DateJul 7, 2022

Final
Final | Div/Share: ₹30.00

Dividend/Share

30.00

Ex DateEx Date

Jul 7, 2022

Cash Dividend

Ex DateEx DateJul 19, 2021

Final
Final | Div/Share: ₹30.00

Dividend/Share

30.00

Ex DateEx Date

Jul 19, 2021

News & Opinions

Glaxosmithkline Pharmaceuticals consolidated net profit rises 37.87% in the June 2024 quarter

2 months agoBusiness Standard
Earnings
Glaxosmithkline Pharmaceuticals consolidated net profit rises 37.87% in the June 2024 quarter

Net profit of Glaxosmithkline Pharmaceuticals rose 37.87% to Rs 182.33 crore in the quarter ended June 2024 as against Rs 132.25 crore during the previous quarter ended June 2023. Sales rose 6.96% to Rs 814.65 crore in the quarter ended June 2024 as against Rs 761.66 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales814.65761.66 7 OPM %28.3018.89 - PBDT265.81180.04 48 PBT249.40163.68 52 NP182.33132.25 38 Powered by Capital Market - Live

2 months agoCapital Market - Live

GSK Pharma Q1 PAT climbs 39% YoY to Rs 182 crore

2 months agoBusiness Standard
Spotlight
GSK Pharma Q1 PAT climbs 39% YoY to Rs 182 crore

Revenue from operations grew by 9.89% year on year (YoY) to Rs 811 crore during the quarter ended June 2024. Profit before exceptional item and tax was at Rs 248.49 crore in the June 2024 quarter, up 53.95% from Rs 161.41 crore recorded in corresponding quarter last year. Total expenses declined 2.45% to Rs 598.36 crore in Q1 FY25 over Q1 FY24. Cost of materials consumed was at Rs 133.33 crore (down 8.35% YoY) while employee benefits expense stood at Rs 151.28 crore (down 8.32% YoY) during the period under review. The drug maker stated that it continued to deliver a strong growth of 10% with key brands such as Calpol, Augmentin, T-Bact and gaining market share. In addition, the respiratory portfolio comprising Nucala and Trelegy delivered a growth of 57% by further improving access to more patients. The paediatric vaccine segment maintained market leadership in the self-pay private market and delivered double-digit growth of 15%. In the adult vaccines segment, GSK continues to build on the momentum from the launch of Shingrix Herpes Zoster Vaccine (recombinant, adjuvanted) to further expand the adult immunisation category in India through its innovative go-to-market (GTM) strategies, stated the pharmaco. Bhushan Akshikar, managing director, GlaxoSmithKline Pharmaceuticals, said, 'We continue our growth momentum across General Medicines and Vaccines portfolios while maintaining profitability. As we celebrate hundred years of our operations in India, we remain committed to pursuing new growth opportunities, enhancing our leadership in key therapeutic areas and advancing our innovative omnichannel strategies to further enhance customer experience.' GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies. The scrip closed 2.49% higher at Rs 2,824.45 on Friday, 2 August 2024. Powered by Capital Market - Live

2 months agoCapital Market - Live

GSK Pharma Q1 results: Net profit rises 37%, revenue up 6.9%

2 months agoBusiness Standard

GSK Pharmaceuticals Q1 results: Net profit jumps 38% to Rs 182.33 crore

2 months agoBusiness Standard

Technical Breakout Stocks: Budget Day volatility! Suzlon, GlaxoSmithkline Pharma and Federal Bank hit fresh 52-week highs - Market Outlook

2 months agoEconomic Times

Stock market update: Stocks that hit 52-week highs on NSE

2 months agoEconomic Times
Corporate
GlaxoSmithKline Pharmaceuticals to convene board meeting

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 2 August 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live

Glaxosmithkline Pharmaceuticals announces change in senior management

3 months agoBusiness Standard